Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
27 sept. 2023 06h30 HE
|
Avalyn Pharma Inc.
Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation by new and current healthcare investors Funds to support Phase 2b development of AP01...
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
18 sept. 2023 12h06 HE
|
Avalyn Pharma Inc.
Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
12 sept. 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, and...
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
11 sept. 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
07 sept. 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
07 août 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
27 juil. 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
15 juin 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
23 mai 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today presented...
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
11 mai 2023 08h00 HE
|
Avalyn Pharma Inc.
- Avalyn CEO to Present in Company Showcase and Moderate Panel Discussion at ATS RIS - - Results from Long-Term Treatment of Pulmonary Fibrosis with AP01 to be Presented at ATS - SEATTLE, May 11,...